PDCD1 and neoplasm: S8B), and the effect of the triple combination in the long-term resulted in significant tumor control and extension of survival compared to MRTX849 + anti–PD-1, even generating one of the eight completely tumor-free mice, which remained tumor free after withdrawal of treatment for 30 days (Fig. 8A).